What question did this study set out to answer?

The aim is to explore the mechanisms, classification, and recent advancements in the diagnosis and treatment of urolithiasis.

May 30, 2026

From History to Innovation: Pathophysiology and the Evolving Landscape ofUrolithiasis Diagnosis and Treatment

Key Points

The aim is to explore the mechanisms, classification, and recent advancements in the diagnosis and treatment of urolithiasis.
Reviewed recent breakthroughs in molecular science and innovative diagnostics for urolithiasis.
Analyzed advancements in treatments, including precision therapies targeting individual molecular pathways.
Examined implications of genetic studies for hereditary susceptibility in urolithiasis.
Innovative diagnostics like Dual-Energy Computed Tomography and machine learning improve non-invasive stone characterization.
Transition from traditional pharmacologic treatments to new drugs targeting molecular mechanisms of stone formation.
Future directions include integrating molecular diagnostics and artificial intelligence for personalized patient management.

Abstract

Urolithiasis is a multicomponent illness described by the production of calcified stones within the urinary tract. It remains an important global health issue due to its frequency, recurrence, and cost. Urine supersaturation, crystal nucleation, development, aggregation, and retention are all steps in the stone formation process that are influenced by environmental, genetic, and metabolic factors. Calcium oxalate and calcium phosphate account for the majority of cases, whereas uric acid or infection stones develop in the context of particular metabolic or infectious conditions. Breakthroughs in molecular science have uncovered mechanisms such as crystal adhesion, oxidative stress, inflammation, and tubular injury, advancing understanding of disease development. The identification of genetic variants in transporters and metabolic enzymes by genetic studies shows hereditary susceptibility. Innovative diagnostics such as Dual-Energy Computed Tomography (DECT), ultra-low-dose imaging, and machine learning now enable accurate non-invasive characterisation of stones. Technologies like Fourier-Transform Infrared (FTIR), Raman, and micro-spectroscopy, complemented by intraoperative sampling, also facilitate enhanced stone composition analysis. Treatment modalities have evolved from traditional pharmacologic agents like citrate, thiazides, and allopurinol to emerging drugs that target molecular pathways of nucleation and aggregation. New precision-based therapies and innovative formulations are designed to reduce recurrence and enhance outcomes. The future direction focuses on incorporating molecular diagnostics, genomics, and artificial intelligence into practice for individualised management. This review discusses the mechanisms, classification, molecular and genetic determinants, and therapeutic breakthroughs in urolithiasis, emphasising the transition from conventional to emerging approaches and indicating future directions for better patient care.

Ask AI

Helpful

Bookmark